Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.

The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma.

We caught up with Lindsay Davies, Chief Scientific Officer of NextCell Pharma, to hear about to hear about the latest advancements in stromal cell therapy in anticipation of her presentation at our Cell & Gene 2024 Congress this November.

Here, we speak to Marta Barisa, Senior Research Fellow at UCL, about switchable CAR-Ts and therapies for solid tumours.

Discover the transformative role of AI in the world of biotechnology. Dive deep into its synergy with 3D modeling, revealing groundbreaking advancements in cell & gene therapy and faster, more efficient drug development cycles.

Adaptimmune has developed from a strategic collaboration with GSK and embarked on a highly successful journey towards developing cancer immunotherapy treatments.

The biotech company BrainStorm is seeking regulatory approval from the FDA for its cell therapy, NurOwn, which has been developed for the treatment of ALS.

Scott Burger, Principal of Advanced Cell and Gene Therapy, discusses some of the recent trends in regulation and policy surrounding cell and gene therapy development.

Regulatory approval is, as ever, a crucial factor to bear in mind during the later phases of clinical trials. Regardless of the cell line approach chosen, keeping a consistent process and product output is key for establishing a successful project without it being hamstrung at the final hurdle.

Following FDA approval for the use of Jemperli in the context of patients with dMMR recurrent or advanced scenarios, the therapeutic's applications are being investigated in registrational enabling studies as monotherapy and as part of combination regimens.

By dropping down from three to two ongoing cell therapies in clinical development, Senti aims to ensure its current financial reserves last into 2024.

Potential treatments which may benefit from the funding increase include CAR-T cell therapies and checkpoint inhibitors, with the end goal of clinical use in cancer patients.

Securing regulatory approval is often the end goal in the development of a new therapeutic product. But what steps can be taken to avoid some of the common curveballs encountered in the industry?

We interview Pedro-Caetano Pinto, Lab Head at the University of Greifswald to learn more about his work with microphysiological systems for advanced kidney and prostate cancer research.

Vasiliki Kalodimou of the NCSR DEMOKRITOS, discusses her work in cell therapy analytics, ahead of Oxford Global's Cell Therapy Analytics Event.

Glyn Stacey, Chief Executive at SSCBio leads a discussion on the current landscape of ‘Cell Therapy Analytics'.

This Commentary piece explores how the production and delivery of NK cells could provide a new option for clinical treatment of illnesses such as myeloid leukaemia, with the potential for scaling approaches to be incorporated into the treatment process.

Oxford Global's Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Advancing The Implementation Of Automation Technologies For Cell Therapy Development' was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market's growth, its priorities, future outlook, and challenges.